Pfizer Partners with Alloy Therapeutics to Develop New Antibody Platform
US pharmaceutical giant Pfizer (NYSE: PFE) has entered into a multi-year partnership with compatriot firm...
Biotech
Novartis to Acquire Anthos Therapeutics for $3.1B, Boosting Factor XI Inhibitor Portfolio
Swiss pharma giant Novartis (NYSE: NVS) announced plans to acquire Anthos Therapeutics, Inc., a cardiometabolic-focused...
Henlius’ Serplulimab Receives EU Approval for Extensive-Stage Small Cell Lung Cancer
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced that it has received marketing approval from...
Jiangsu Vcare PharmaTech Secures RMB200 Million in Series C+ Financing
Jiangsu Vcare PharmaTech Co., Ltd., a China – based high – tech pharmaceutical company, has...
China Medical System Partners with MabGeek for Innovative Drug MG-K10
China Medical System Holdings (CMS; HKG: 0867) has announced a new license agreement with MabGeek...
Simcere Licenses Fermion’s AI-Enabled Painkiller FZ002-037
China-based Simcere Pharmaceutical Group Limited (HKG: 2096) has announced a licensing agreement with compatriot firm...
Johnson & Johnson to Acquire Intra-Cellular Therapies for $14.6B
US-based Johnson & Johnson (J&J, NYSE: JNJ) is set to acquire all outstanding shares of...
Keymed Biosciences Licenses CM313 to Timberlyne Therapeutics for Global Development
China-based Keymed Biosciences Inc. (HKG: 2162) has entered into a licensing agreement with US firm...
Hangzhou Highlightll Pharma Completes Pre-Series C Financing Round
China-based Hangzhou Highlightll Pharmaceutical Co., Ltd has announced the successful completion of a Pre-Series C...
Ascentage Pharma Announces Secondary Offering on Nasdaq, Expanding Global Reach
China-based Ascentage Pharma (HKG: 6855) has unveiled plans for a secondary offering of up to...
Zhejiang Huahai Pharmaceutical’s Subsidiary Huaota Bio Secures $27.4 Million Investment
Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that its macromolecular drug-focused subsidiary, Shanghai...
BeiGene Rebrands to BeOne Medicines Ltd, Ticker Symbol Changes to “ONC”
China-based BeiGene Ltd, listed on Nasdaq (NASDAQ: BGNE, HKG: 6160, SHA: 688235), has announced a...
RAPT Therapeutics Secures Ex-China Rights to Jemincare Group’s Anti-IgE Antibody JYB1904
US-based biopharmaceutical company RAPT Therapeutics Inc. (NASDAQ: RAPT) has announced that it has obtained the...
AbbVie Acquires Roche’s Nimble Therapeutics to Boost Immunology Pipeline
US pharmaceutical company AbbVie (NYSE: ABBV) has reached an agreement to acquire Swiss pharmaceutical giant...
Wuhan Kaideweisi Biotechnology Secures Series B Funding for Gynecologic Oncology Expansion
Wuhan Kaideweisi Biotechnology Co., Ltd, a specialist in gynecologic oncology in China, has reportedly raised...
Laekna, Inc. Initiates IND-Enabling Study for Monoclonal Antibody LAE123 in Severe Diseases
Sino-US biotech company Laekna, Inc. (HKG: 2105) has announced the initiation of an Investigational New...
Zai Lab Ltd Partners with Pfizer for Commercialization of Xacduro in China
China-based biotechnology company Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced a strategic collaboration...
Shanghai Junshi Biosciences Enters Licensing Agreement for Dual-Targeted Fusion Proteins
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a China-based biopharmaceutical company, has announced...
LaNova Medicines Inks Licensing Deal with Sino Biopharmaceutical for Cancer Therapies in China
Shanghai-based LaNova Medicines Ltd, a developer of cancer therapies, has announced another licensing deal, signing...
Zai Lab Ltd Announces Secondary Public Offering Worth $230 Million
Zai Lab Ltd (ZLAB; NASDAQ: ZLAB; HKG: 9688), a leading biopharmaceutical company, is set to...